United Therapeutics Corporation (UTHR) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $800.00K; Additional Paid in Capital, Common StockUSD $2.90B; Treasury Stock, Common, ValueUSD $5.64B.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $800.00K; Additional Paid in Capital, Common StockUSD $2.52B; Treasury Stock, Common, ValueUSD $5.44B.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $800.00K; Additional Paid in Capital, Common StockUSD $2.80B; Treasury Stock, Common, ValueUSD $4.26B.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $800.00K; Additional Paid in Capital, Common StockUSD $2.66B; Treasury Stock, Common, ValueUSD $4.26B.
United Therapeutics Corporation Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Treasury Stock, Common, Value USD | Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Treasury Stock, Common, Shares shares | Treasury Stock, Value, Acquired, Cost Method USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Treasury Stock, Value USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt USD | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature USD | Treasury Stock, Shares, Acquired shares | Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax USD | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation USD | Treasury Stock, Shares shares |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $800.00K | $2.90B | $5.64B | (m) | $-16.20M | $9.16B | $6.40B | 35.35M | 3 month · $0.00 6 month · $1.50B | 3 month · $43.40M 6 month · $77.30M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $0.00 | $800.00K | $2.52B | $5.44B | (m) | $-10.20M | $8.83B | $5.90B | 34.97M | 3 month · $1.50B | 3 month · $33.90M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $0.00 | $800.00K | $2.80B | $4.26B | $-5.60M | $900.00K | $8.56B | $7.10B | 32.81M | 12 month · $1.00B | 12 month · $148.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $0.00 | $800.00K | $2.66B | $4.26B | (m) | $100.00K | $8.19B | $6.59B | 32.81M | 3 month · $1.00B 9 month · $1.00B | 3 month · $39.10M 9 month · $109.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $0.00 | $800.00K | $2.79B | $3.47B | (m) | $0.00 | $7.85B | $7.17B | 30.17M | (m) | 3 month · $37.80M 6 month · $70.40M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $0.00 | $800.00K | $2.74B | $3.47B | (m) | $-1.20M | $7.54B | $6.81B | 30.17M | (m) | 3 month · $32.60M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $0.00 | $800.00K | $2.70B | $3.47B | $-11.00M | $-3.40M | $7.22B | $6.44B | 30.17M | 12 month · $1.00B | 12 month · $111.70M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $0.00 | $700.00K | $2.65B | $3.48B | (m) | $7.40M | $6.92B | $6.10B | 30.17M | 3 month · $0.00 9 month · $1.00B | 3 month · $35.80M 9 month · $85.30M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $0.00 | $700.00K | $2.54B | $3.44B | (m) | $-14.90M | $6.61B | $5.70B | 30.08M | (m) | 3 month · $27.80M 6 month · $49.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $0.00 | $700.00K | $2.41B | $3.39B | (m) | $-15.60M | $6.33B | $5.34B | 29.89M | (m) | 3 month · $21.70M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $0.00 | $700.00K | $2.55B | $2.58B | $-15.90M | $-12.80M | $6.03B | $5.98B | 26.62M | (m) | 12 month · $69.80M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $0.00 | $700.00K | $2.52B | $2.58B | (m) | $-43.70M | $5.81B | $5.71B | 26.62M | (m) | 3 month · $19.00M 9 month · $52.30M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $0.00 | $700.00K | $2.50B | $2.58B | (m) | $-50.60M | $5.54B | $5.41B | 26.62M | (m) | 3 month · $15.70M 6 month · $33.30M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $0.00 | $700.00K | $2.46B | $2.58B | (m) | $-38.80M | $5.28B | $5.12B | 26.62M | (m) | 3 month · $17.60M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $0.00 | $700.00K | $2.39B | $2.58B | $-18.80M | $-55.50M | $5.04B | $4.80B | 26.62M | (m) | 12 month · $60.10M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $0.00 | $700.00K | $2.31B | $2.58B | (m) | $-84.10M | $4.91B | $4.56B | 26.62M | (m) | 3 month · $16.10M 9 month · $41.80M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $0.00 | $700.00K | $2.29B | $2.58B | (m) | $-65.50M | $4.67B | $4.32B | 26.62M | (m) | 3 month · $13.40M 6 month · $25.70M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $0.00 | $700.00K | $2.25B | $2.58B | (m) | $-54.30M | $4.55B | $4.18B | 26.62M | (m) | 3 month · $12.30M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $0.00 | $700.00K | $2.25B | $2.58B | $500.00K | $-23.00M | $4.32B | $3.96B | 26.62M | (m) | 12 month · $51.90M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $0.00 | $700.00K | $2.23B | $2.58B | (m) | $-20.10M | $4.20B | $3.83B | 26.62M | (m) | 3 month · $12.40M 9 month · $39.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $0.00 | $700.00K | $2.20B | $2.58B | (m) | $-18.60M | $4.04B | $3.64B | 26.62M | (m) | 3 month · $12.70M 6 month · $27.10M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $0.00 | $700.00K | $2.17B | $2.58B | (m) | $-16.80M | $3.87B | $3.45B | 26.62M | (m) | 3 month · $14.40M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $0.00 | $700.00K | $2.15B | $2.58B | $6.70M | $-14.20M | $3.84B | $3.40B | 26.62M | (m) | 12 month · $66.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $0.00 | $700.00K | $2.13B | $2.58B | (m) | $-4.50M | $3.74B | $3.28B | 26.62M | (m) | 3 month · $15.00M 9 month · $50.80M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $0.00 | $700.00K | $2.11B | $2.58B | (m) | $-2.10M | $3.57B | $3.09B | 26.62M | (m) | 3 month · $15.10M 6 month · $35.80M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $700.00K | $2.07B | $2.58B | (m) | $-3.50M | $3.46B | $2.95B | 26.62M | (m) | 3 month · $20.70M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $0.00 | $700.00K | $2.05B | $2.58B | $0.00 | $-14.20M | $3.33B | $2.78B | 26.62M | (m) | 12 month · $85.10M | (m) | (m) | 12 month · $10.80M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $700.00K | $2.03B | $2.58B | (m) | $-4.10M | $3.27B | $2.72B | 26.62M | (m) | 3 month · $22.50M 9 month · $63.00M | (m) | (m) | 9 month · $10.80M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $700.00K | $2.00B | $2.58B | (m) | $-5.00M | $3.14B | $2.56B | 26.62M | (m) | 3 month · $22.20M 6 month · $40.50M | (m) | (m) | 3 month · $10.80M 6 month · $10.80M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $700.00K | $1.97B | $2.58B | (m) | $-5.20M | $2.94B | $2.32B | 26.62M | (m) | 3 month · $18.30M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $700.00K | $1.94B | $2.58B | (m) | $-7.90M | $3.43B | $2.79B | 26.62M | (m) | 12 month · $66.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $700.00K | $1.92B | $2.58B | (m) | $-22.20M | $3.37B | $2.69B | 26.62M | (m) | 3 month · $18.60M 9 month · $50.30M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $700.00K | $1.90B | $2.58B | (m) | $-21.90M | $3.26B | $2.57B | 26.62M | (m) | 3 month · $17.80M 6 month · $31.70M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $700.00K | $1.88B | $2.58B | (m) | $-21.70M | $3.09B | $2.37B | 26.62M | (m) | 3 month · $13.90M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $700.00K | $1.85B | $2.58B | (m) | $-19.60M | $2.85B | $2.10B | 26.62M | 12 month · $250.00M | 12 month · $46.40M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $700.00K | $1.84B | $2.58B | (m) | $-16.80M | $2.83B | $2.07B | 26.62M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $700.00K | $1.79B | $2.54B | (m) | $-16.60M | $2.55B | $1.78B | 26.33M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $700.00K | $1.80B | $2.33B | (m) | $-16.70M | $2.61B | $2.07B | 24.64M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $700.00K | $1.81B | $2.38B | (m) | $-16.80M | $2.43B | $1.85B | 26.38M | 12 month · $500.00M | 12 month · $27.30M | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $5.90M | (m) |
| 2016-09-30 | (m) | $700.00K | $1.84B | $2.31B | (m) | $-16.80M | $2.32B | $1.84B | 26.63M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $700.00K | $1.83B | (m) | (m) | $-14.70M | $2.16B | $1.81B | (m) | (m) | (m) | $2.17B | (m) | (m) | (m) | (m) | (m) | (m) | 25.49M |
| 2016-03-31 | (m) | $700.00K | $1.80B | (m) | (m) | $-19.80M | $1.96B | $1.71B | (m) | (m) | (m) | $2.03B | (m) | (m) | (m) | (m) | (m) | (m) | 24.21M |
| 2015-12-31 | (m) | $700.00K | $1.79B | $1.90B | (m) | $-20.40M | $1.72B | $1.59B | 23.23M | 12 month · $394.50M | 12 month · $6.10M | $1.90B | (m) | (m) | (m) | (m) | (m) | 12 month · $37.40M | 23.23M |
| 2015-09-30 | (m) | $685.00K | $1.72B | (m) | (m) | $-21.93M | $1.62B | $1.47B | (m) | (m) | (m) | $1.85B | (m) | (m) | (m) | (m) | (m) | (m) | 22.88M |
| 2015-06-30 | (m) | $682.00K | $1.69B | (m) | (m) | $-19.93M | $1.15B | $1.04B | (m) | (m) | (m) | $1.79B | (m) | (m) | (m) | (m) | 6 month · $-481.00K | (m) | 22.50M |
| 2015-03-31 | (m) | $665.00K | $1.43B | (m) | (m) | $-21.64M | $1.05B | $1.09B | (m) | (m) | (m) | $1.37B | (m) | (m) | (m) | (m) | 3 month · $-333.00K | (m) | 20.08M |
| 2014-12-31 | (m) | $660.00K | $1.38B | (m) | (m) | $-16.73M | $1.07B | $1.24B | (m) | 12 month · $483.10M | 12 month · $30.60M | $1.19B | (m) | (m) | (m) | (m) | 12 month · $-904.00K | 12 month · $30.80M | 18.88M |
| 2014-09-30 | (m) | $642.00K | $1.16B | (m) | (m) | $-16.93M | $952.18M | $1.18B | (m) | 3 month · $25.60M | (m) | $916.60M | (m) | (m) | (m) | (m) | 9 month · $-678.00K | (m) | 16.80M |
| 2014-06-30 | (m) | $638.00K | $1.10B | (m) | (m) | $-14.63M | $977.42M | $1.17B | (m) | (m) | (m) | $891.00M | (m) | (m) | (m) | (m) | 6 month · $-452.00K | (m) | 16.53M |
| 2014-03-31 | (m) | $633.00K | $1.08B | (m) | (m) | $-15.64M | $865.56M | $1.32B | (m) | (m) | (m) | $611.07M | (m) | (m) | (m) | (m) | 3 month · $-226.00K | (m) | 13.65M |
| 2013-12-31 | (m) | $630.00K | $1.06B | (m) | (m) | $-13.18M | $728.04M | $1.26B | (m) | 12 month · $42.44M | 12 month · $36.90M | $513.44M | (m) | (m) | (m) | (m) | 12 month · $-1.02M | 12 month · $9.30M | 12.63M |
| 2013-09-30 | (m) | $628.00K | $1.03B | (m) | (m) | $-15.06M | $758.35M | $1.26B | (m) | 9 month · $42.40M | (m) | $513.44M | (m) | (m) | (m) | 9 month · 709.00K | 9 month · $-767.00K | (m) | 12.63M |
| 2013-06-30 | (m) | $625.00K | $999.68M | (m) | (m) | $-17.11M | $695.67M | $1.17B | (m) | 6 month · $42.40M | (m) | $513.44M | (m) | (m) | (m) | 6 month · 709.00K | (m) | (m) | 12.63M |
| 2013-03-31 | (m) | $623.00K | $1.03B | (m) | (m) | $-16.96M | $615.80M | $1.15B | (m) | 3 month · $5.90M | (m) | $476.90M | (m) | (m) | (m) | 3 month · 99.10K | (m) | (m) | 12.02M |
| 2012-12-31 | (m) | $621.00K | $1.02B | (m) | (m) | $-14.96M | $553.48M | $1.08B | (m) | 12 month · $188.00M | 12 month · $3.26M | $471.00M | (m) | (m) | (m) | (m) | (m) | 12 month · $3.05M | 11.92M |
| 2012-11-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 1 month · $100.00M | (m) | (m) | (m) | (m) | (m) | 1 month · 2.00M | (m) | (m) | (m) |
| 2012-09-30 | (m) | $619.00K | $1.01B | (m) | (m) | $-9.52M | $470.23M | $1.06B | (m) | 3 month · $42.90M | (m) | $413.92M | (m) | (m) | (m) | 3 month · 788.29K | (m) | (m) | 10.73M |
| 2012-06-30 | (m) | $617.00K | $998.78M | (m) | (m) | $-10.91M | $392.11M | $1.01B | (m) | (m) | (m) | $371.00M | (m) | (m) | (m) | (m) | (m) | (m) | 9.94M |
| 2012-05-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 1 month · $88.00M | (m) | (m) | (m) | (m) | (m) | 1 month · 2.00M | (m) | (m) | (m) |
| 2012-03-31 | (m) | $616.00K | $996.77M | (m) | (m) | $-9.54M | $319.80M | $1.02B | (m) | (m) | (m) | $283.00M | (m) | (m) | (m) | (m) | (m) | (m) | 7.90M |
| 2011-12-31 | (m) | $615.00K | $992.72M | (m) | (m) | $-10.88M | $249.04M | $948.49M | (m) | 12 month · $211.77M | 12 month · $527.00K | $283.00M | (m) | 12 month · $56.19M | 12 month · $56.19M | (m) | (m) | 12 month · $11.35M | 7.90M |
| 2011-10-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 1 month · $212.00M | (m) | (m) | (m) | (m) | (m) | 1 month · 4.70M | (m) | (m) | (m) |
| 2011-09-30 | (m) | $608.00K | $959.30M | (m) | (m) | $-10.64M | $205.85M | $1.08B | (m) | (m) | (m) | $70.15M | (m) | (m) | (m) | (m) | (m) | (m) | 2.50M |
| 2011-06-30 | (m) | $608.00K | $958.96M | (m) | (m) | $-8.52M | $121.45M | (m) | (m) | (m) | (m) | $70.15M | $1.00B | (m) | (m) | (m) | (m) | (m) | 2.50M |
| 2011-03-31 | (m) | $605.00K | $953.53M | (m) | (m) | $-7.33M | $47.56M | (m) | (m) | (m) | (m) | $70.15M | $924.21M | (m) | (m) | (m) | (m) | (m) | 2.50M |
| 2010-12-31 | (m) | $600.00K | $928.69M | (m) | (m) | $-9.18M | $31.17M | $883.89M | (m) | (m) | 12 month · $22.65M | $67.40M | $883.89M | (m) | (m) | (m) | (m) | 12 month · $23.83M | 2.46M |
| 2010-09-30 | (m) | $592.00K | $892.11M | (m) | (m) | $-6.19M | $21.63M | (m) | (m) | (m) | (m) | $67.40M | $840.73M | (m) | (m) | (m) | (m) | (m) | 2.46M |
| 2010-06-30 | (m) | $589.00K | $874.43M | (m) | (m) | $-7.22M | $-18.11M | (m) | (m) | (m) | (m) | $67.39M | $782.30M | (m) | (m) | (m) | (m) | (m) | 2.46M |
| 2009-12-31 | (m) | $567.00K | $798.90M | (m) | (m) | $-4.31M | $-74.75M | $653.01M | (m) | (m) | 12 month · $40.14M | $67.39M | $653.01M | (m) | (m) | (m) | (m) | 12 month · $4.41M | 2.46M |
| 2008-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $555.33M | (m) | (m) | 12 month · $28.47M | (m) | $555.33M | (m) | (m) | (m) | (m) | 12 month · $38.36M | (m) |
| 2007-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $352.13M | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |